| 2016-10-07 07:51:57|
CELG 07:51 10/07 10/07/16
Celgene to present data evaluating the use of Abraxane as foundational treatment
Celgene Corporation announced results from multiple sponsored and independent studies will be presented during the European Society of Medical Oncology 2016 Annual Meeting evaluating the use of ABRAXANE as a foundational treatment, either alone or in combination with novel agents and novel regimens, for patients with traditionally challenging cancers, including metastatic pancreatic cancer, metastatic breast cancer and advanced non-small cell lung cancer. "Celgene continues to evaluate the safety and efficacy of ABRAXANE in patients with particularly challenging advanced diseases or with co-morbidities that limit their treatment options," said Michael Pehl, President, Hematology and Oncology for Celgene. "These data continue to shape our understanding of these difficult to treat diseases which will help evolve the current and future treatment landscapes in areas where there have been historically limited treatment options available to patients."